G&E Herbal Biotechnology Co., Ltd.
G&E Herbal Biotechnology Co., Ltd. engages in development and commercialization of novel botanical extraction technology and products in Taiwan. It offers Hepanamin capsules; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as adult products, in… Read more
G&E Herbal Biotechnology Co., Ltd. (4911) - Total Assets
Latest total assets as of September 2025: NT$967.19 Million TWD
Based on the latest financial reports, G&E Herbal Biotechnology Co., Ltd. (4911) holds total assets worth NT$967.19 Million TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
G&E Herbal Biotechnology Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how G&E Herbal Biotechnology Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
G&E Herbal Biotechnology Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
G&E Herbal Biotechnology Co., Ltd.'s total assets of NT$967.19 Million consist of 47.0% current assets and 53.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.9% |
| Accounts Receivable | NT$17.80 Million | 1.9% |
| Inventory | NT$21.71 Million | 2.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how G&E Herbal Biotechnology Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: G&E Herbal Biotechnology Co., Ltd.'s current assets represent 47.0% of total assets in 2024, an increase from 19.6% in 2021.
- Cash Position: Cash and equivalents constituted 15.9% of total assets in 2024, up from 1.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 2.3% of total assets.
G&E Herbal Biotechnology Co., Ltd. Competitors by Total Assets
Key competitors of G&E Herbal Biotechnology Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
G&E Herbal Biotechnology Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - G&E Herbal Biotechnology Co., Ltd. generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, G&E Herbal Biotechnology Co., Ltd. generates $ 10.64 in net profit.
G&E Herbal Biotechnology Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.00 | 7.79 | 7.79 |
| Quick Ratio | 6.64 | 7.37 | 7.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$397.71 Million | NT$ 291.77 Million | NT$ 291.77 Million |
G&E Herbal Biotechnology Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between G&E Herbal Biotechnology Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.43 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | NT$959.17 Million |
| Market Capitalization | $49.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values G&E Herbal Biotechnology Co., Ltd.'s assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: G&E Herbal Biotechnology Co., Ltd.'s assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for G&E Herbal Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual total assets of G&E Herbal Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$959.17 Million | +8.62% |
| 2023-12-31 | NT$883.10 Million | +12.82% |
| 2022-12-31 | NT$782.77 Million | +13.10% |
| 2021-12-31 | NT$692.13 Million | -- |